Recombinant Human Anti-VEEV E2 Antibody scFv Fragment (3B4C-4) (CAT#: PSBL-735)

1. Q 1: Can this antibody fragment be used in vivo for therapeutic applications?

   A: While the 3B4C-4 scFv fragment has shown promising results in vitro, further preclinical animal studies are recommended to confirm its safety and efficacy in vivo before considering therapeutic applications in humans.

2. Q 2: Does the antibody fragment form aggregates, and what are the implications for its use?

   A: The 3B4C-4 scFv segment was designed to decrease aggregation. Aggregation may occur over time or under inadequate storage conditions. Aggregates have the potential to diminish efficacy and safety, highlighting the importance of correct storage and management.

3. Q 3: How does the antibody fragment perform in a competitive binding assay?

   A: The 3B4C-4 scFv fragment performs admirably in competitive binding experiments, retaining high specificity and affinity even in the presence of competing molecules, making it perfect for use in research.

View the frequently asked questions answered by Creative Biolabs Support.